[vc_row][vc_column][vc_column_text dp_text_size=”size-4″]In a late-stage experiment including patients with advanced or recurrent endometrial cancer, Imfinzi and Lynparza from AstraZeneca showed promising outcomes when combined with platinum-based chemotherapy.
ALSO READ: A New mRNA Vaccine for Pancreatic Cancer Shows Hopeful Results
In comparison to standard-of-care chemotherapy, either Imfinzi + Lynparza or Imfinzi alone as maintenance therapy improved progression-free survival (PFS) statistically significantly, according to the British pharmaceutical company.[/vc_column_text][/vc_column][/vc_row]
